金色化物Rg1提高了学习和记忆能力,并通过ERK/CREB/BDNF信号通路减少了性老鼠的神经元亡
Jiawei Zhang1, Chaochao Zhu2, Yun Jin1
1Department of Neurosurgery, The First People's Hospital of Tongxiang, Tongxiang, 314500, Zhejiang, China.
Biochemical and biophysical research communications
|July 14, 2023
概括
银化物Rg1通过激活ERK/CREB/BDNF通路,改善了性老鼠的学习和记忆. 这种治疗减少了神经元亡,氧化应激和炎症,为提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 是一种慢性神经系统疾病,其特点是经常性发作和相关的认知缺陷.
- 神经细胞亡和氧化应激在的病理生理学中起着重要作用.
- 细胞外信号调节激酶 (ERK) /cAMP反应元素结合蛋白 (CREB) /脑衍生神经营养因子 (BDNF) 途径与神经元的生存和可塑性有关.
研究的目的:
- 在性鼠模型中研究金氏化物Rg1对学习和记忆的作用.
- 探索ERK/CREB/BDNF途径在金氏酸Rg1神经保护作用中的作用.
- 评估金氏化物Rg1对神经元亡,氧化应激和脑炎症的影响.
主要方法:
- 由化诱导的性大鼠模型.
- 给予不同剂量的金氏化物Rg1 (20,30,40毫克/公斤) 或载体.
- 使用莫里斯水迷宫评估认知功能.
- 通过Nissl和TUNEL测定以及HE染色来评估神经元亡和形态.
- 使用ELISA测量氧化应激标记物 (ROS,MDA,TNF-α,SOD) 和炎症性细胞因子 (IL-10).
- 西部斑点分析以确定Bcl-2,Bax,ERK,p-ERK,CREB,p-CREB和BDNF的水平.
- 与PD98059的干预,一个ERK通路阻塞.
主要成果:
- 银胺Rg1治疗显著改善了性大鼠的认知功能,减少了逃跑延迟时间,增加了目标象限的居住时间.
- 治疗恢复了神经元形态,减少了神经元亡,降低了氧化应激标志物 (MDA,ROS,TNF-α) 和炎症性细胞因子的水平.
- 银化物Rg1的给药提高了p-ERK,p-CREB和BDNF的表达,这表明ERK/CREB/BDNF通路的激活.
- 用PD98059抑制ERK通路减弱了人参化物Rg1.1.的有益作用.
结论:
- 金色化物Rg1在性老鼠模型中显示出显著的神经保护作用.
- 人参化物Rg1的治疗效益与ERK/CREB/BDNF信号通路的激活有关.
- 丁胺Rg1可以通过减轻神经元亡,氧化应激和认知功能障碍,作为的潜在治疗剂.
更多相关视频
09:06Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
9.6K
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.1K
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
215
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
215
Antiepileptic Drugs: GABAergic Pathway Potentiators
467
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
467
